Overview
The study is designed to provide long term clinical and virologic follow up in subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (DAAs)-based therapy. This long term follow up study is observational and no treatment is provided for HCV infection.
Eligibility
Inclusion Criteria:
- Patients with chronic hepatitis C treated with interferon-based therapy or direct-acting agents (DAAs)-based regimen;
- Provide written, informed consent;
- Be willing and able to comply with the visit schedule and protocol-mandated procedures.
Exclusion Criteria:
- Individuals planning to start a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up time frame;
- History of clinically significant illness or any other major medical disorder that may interfere with follow up, assessments, or compliance with the protocol.
- Inability to provide written informed consent.